Myriad Genetics Inc., which produces diagnostic tests that determine a person’s susceptibility to genetically linked cancers, is projecting it will generate revenue of $690 million to $710 million for its 2014 fiscal year.
And it expects that revenue will result in earnings per share of $1.87 to $1.94 next year, or 6 percent to 10 percent growth.
Myriad offered that revenue and earnings guidance on Tuesday when it reported the financial results for its recently competed fourth quarter and 2013 f...
Share this post
← Back to Utah